United States Patent 12,005,052: Roflumilast Topical Formulation Claims and Patent Landscape
United States Patent 12,005,052 protects topical roflumilast compositions defined by both their ingredient combinations and, in claim 1, a plasma half-life of 3 to 5 days. The broadest practical coverage centers on roflumilast at 0.05% to 1.0% w/w combined with water, diethylene glycol monoethyl ether, and an emulsifier blend containing cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate.
The patent is formulation-focused. It does not broadly claim roflumilast as an active ingredient, treatment of a dermatologic disease, or every topical dosage form. Its commercial significance depends on whether an accused product uses the specified emulsifier system, solvent concentration, dosage form, and pharmacokinetic profile.
What does United States Patent 12,005,052 protect?
The patent claims two related formulation architectures:
| Claim group |
Core subject matter |
Main quantitative limitations |
| Claims 1-6 |
Topical pharmaceutical composition with a defined emulsifier blend and pharmacokinetic result |
Roflumilast 0.05%-1.0% w/w; plasma half-life 3-5 days |
| Claims 7-9 |
Topical roflumilast foam or cream with defined solvent and emulsifier ranges |
Roflumilast 0.05%-1.0%; diethylene glycol monoethyl ether 10%-30%; emulsifier blend 1%-25% |
The required emulsifier blend consists of:
- Cetostearyl alcohol;
- Dicetyl phosphate; and
- Ceteth-10 phosphate.
The claims therefore combine composition-of-matter limitations with formulation-performance limitations. A product that contains roflumilast and diethylene glycol monoethyl ether but uses a different emulsifier system would not literally satisfy the central emulsifier limitation.
How broad is independent claim 1?
Claim 1 requires all of the following elements:
- A pharmaceutical composition;
- Topical administration;
- Roflumilast at 0.05% to 1.0% w/w;
- Water;
- Diethylene glycol monoethyl ether;
- An emulsifier blend containing cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate; and
- A roflumilast plasma half-life of 3 to 5 days after topical administration.
The claim is broad as to dosage form. It does not expressly require a foam or cream. A lotion, emulsion, gel, or other topical format could fall within claim 1 if it contains the required ingredients and produces the claimed half-life.
The half-life limitation narrows the claim in one respect and creates an enforcement issue in another. A patentee would need to establish that the accused composition produces a plasma half-life within the claimed range. The relevant evidence could include clinical pharmacokinetic data, population pharmacokinetic modeling, regulatory submissions, or a validated study using the accused formulation.
A formulation with the listed ingredients but a demonstrated plasma half-life outside the 3-to-5-day range could present a literal infringement defense. The strength of that defense would depend on whether the half-life is interpreted as an inherent property of the composition, a measured result under specified conditions, or a functional limitation requiring proof in the accused product.
What do claims 2 through 6 add?
Claims 2 through 6 narrow claim 1 through specific concentration combinations.
| Claim |
Added limitation |
| Claim 2 |
Emulsifier blend at about 10% w/w |
| Claim 3 |
Diethylene glycol monoethyl ether at about 25% w/w |
| Claim 4 |
Defective or incomplete concentration language: "comprises w/w roflumilast" |
| Claim 5 |
Claim 4 composition with about 10% w/w emulsifier blend |
| Claim 6 |
Claim 4 composition with about 25% w/w diethylene glycol monoethyl ether |
Claims 2 and 3 are commercially important because they identify a formulation corridor centered on 10% emulsifier blend and 25% diethylene glycol monoethyl ether.
The term "about" introduces ordinary claim-construction questions. Courts generally assess the scope of "about" in light of the specification, prosecution history, measurement precision, and technical meaning. A formulation containing 9.5% or 10.5% emulsifier blend may create a closer infringement question than one containing 5% or 15%.
Claim 4 appears facially incomplete. It states that the composition "comprises w/w roflumilast" without specifying a numerical amount. That defect may affect enforceability, construction, or validity. The legal effect depends on the issued patent record, prosecution history, correction certificates, and the specification. Claims 5 and 6 inherit the uncertainty because each depends from claim 4.
How broad is independent claim 7?
Claim 7 is the principal composition-and-dosage-form claim. It requires:
- Roflumilast at 0.05% to 1.0% w/w;
- Water q.s. to 100% w/w;
- Diethylene glycol monoethyl ether at 10% to 30% w/w;
- The specified emulsifier blend at 1% to 25% w/w; and
- A foam or cream dosage form.
Unlike claim 1, claim 7 does not expressly include the 3-to-5-day plasma half-life limitation. That distinction materially strengthens claim 7 from an enforcement perspective because infringement can be assessed from formulation composition and dosage form without first proving a pharmacokinetic result.
Claim 7 also has a wider numerical range than claims 2 and 3:
- Diethylene glycol monoethyl ether: 10%-30% w/w;
- Emulsifier blend: 1%-25% w/w.
A competing cream containing 25% diethylene glycol monoethyl ether and 10% of the specified emulsifier blend would fall within the express numerical ranges, assuming it also contains roflumilast within the claimed concentration and qualifies as a cream.
What formulations are protected by claims 8 and 9?
Claims 8 and 9 provide narrower commercial embodiments.
Claim 8: Foam formulation
Claim 8 requires a foam containing:
- Roflumilast within claim 7's concentration range;
- 25% w/w diethylene glycol monoethyl ether;
- 2% w/w emulsifier blend;
- White petrolatum; and
- Isopropyl palmitate.
This is a narrow combination claim. A competing foam that omits white petrolatum, replaces isopropyl palmitate, or uses a different emulsifier system may avoid literal infringement even if it contains roflumilast and diethylene glycol monoethyl ether.
Claim 9: Cream formulation
Claim 9 requires a cream containing:
- Roflumilast within claim 7's concentration range;
- 25% w/w diethylene glycol monoethyl ether;
- 10% w/w emulsifier blend;
- 10.0% w/w white petrolatum; and
- 5.0% w/w isopropyl palmitate.
Claim 9 is the most formulation-specific claim in the set. It can provide strong coverage against a close-copy cream but offers a clear design-around path through changes to the emollient system, emulsifier concentration, solvent concentration, or dosage form.
How do the claims compare with topical roflumilast products?
Topical roflumilast products have been developed and marketed for inflammatory dermatologic conditions, including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The FDA-approved products include cream and foam presentations under the Zoryve brand. The FDA label identifies roflumilast as a topical phosphodiesterase-4 inhibitor and describes product-specific inactive ingredients and administration instructions. [2-4]
The relevant comparison is formulation-specific rather than active-ingredient-specific.
| Product characteristic |
Patent 12,005,052 |
Commercial relevance |
| Active ingredient |
Roflumilast |
Common to the protected products |
| Active concentration |
0.05%-1.0% w/w |
Covers common topical strengths, including 0.3% products |
| Diethylene glycol monoethyl ether |
Required by claims 1 and 7 |
Key solvent limitation |
| Cetostearyl alcohol |
Required emulsifier component |
Required for literal infringement |
| Dicetyl phosphate |
Required emulsifier component |
Required for literal infringement |
| Ceteth-10 phosphate |
Required emulsifier component |
Required for literal infringement |
| Foam |
Expressly covered by claims 7 and 8 |
Relevant to foam products |
| Cream |
Expressly covered by claims 7 and 9 |
Relevant to cream products |
| White petrolatum and isopropyl palmitate |
Required in claims 8 or 9 |
Narrows the claims substantially |
| 3-to-5-day plasma half-life |
Required by claim 1 and its dependents |
Not required by claim 7 |
The presence of an ingredient in an FDA label does not independently establish patent infringement. The concentration, combination, dosage form, and claim interpretation remain determinative.
What is the Orange Book status of Patent 12,005,052?
A patent number is not automatically an Orange Book-listed patent. Listing depends on the approved drug application, the patent's relationship to the drug substance, drug product, or method of use, and FDA listing procedures. FDA regulations distinguish patents that claim the approved drug, its formulation or composition, or an approved method of use. [5]
For a topical roflumilast product, the most relevant listing category would generally be a drug-product or formulation patent rather than a drug-substance patent. Claims 1-9 are directed to compositions and therefore would be evaluated as formulation claims.
If listed for an approved roflumilast product, the patent could affect:
- ANDA certification strategy;
- Paragraph IV notice;
- FDA approval timing;
- Regulatory exclusivity analysis; and
- Patent litigation risk.
Orange Book listing alone would not establish that every roflumilast product infringes. The listing must correspond to the approved formulation and the scope of the asserted claims.
When does United States Patent 12,005,052 lose exclusivity?
The expiration date cannot be calculated from the claim language alone. Patent term generally runs for 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory provisions. [6]
The relevant commercial timeline should distinguish:
| Exclusivity type |
Effect |
| Patent term |
Depends on priority and adjustment data |
| FDA new chemical entity exclusivity |
Generally not central to roflumilast if the active ingredient was previously approved |
| FDA three-year exclusivity |
May apply to certain new clinical investigations, depending on the approval |
| Orphan-drug exclusivity |
Depends on disease and indication designation |
| Pediatric exclusivity |
Can add six months if granted |
| Orange Book patent listing |
Creates a regulatory litigation framework but does not extend the patent term |
| Paragraph IV litigation stay |
Can delay approval for up to 30 months under applicable conditions |
A patent expiration date should therefore be taken from the USPTO patent record and reconciled with any terminal disclaimer or patent-term adjustment. The issue date alone is not a reliable expiration-date calculation.
What generic entry risks exist for roflumilast?
Roflumilast is a small molecule, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply. A generic applicant would normally use the ANDA pathway under section 505(j) if it can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with the applicable reference-product requirements. [7]
For topical roflumilast, generic entry risk is divided into four categories:
Formulation overlap
A generic using the same solvent and emulsifier system may face direct infringement exposure under claims 1 or 7. A cream using the concentrations in claim 9 would face the highest literal-overlap risk.
Bioequivalence and local delivery
Topical products can present complex bioequivalence issues because systemic exposure may not fully capture local skin delivery. FDA has issued product-specific guidance for certain topical products and may evaluate Q1/Q2 sameness, formulation composition, physical properties, and comparative performance. [8]
Paragraph IV litigation
If the patent is listed in the Orange Book for the relevant reference product, an ANDA applicant could submit a Paragraph IV certification. The patent holder could then sue within the statutory period, potentially triggering a 30-month stay of approval.
Design-around formulation
A generic can reduce risk by changing one or more claim-critical elements:
- Replace diethylene glycol monoethyl ether with another solvent;
- Use a different emulsifier system;
- Alter the ratio of cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate;
- Develop a non-cream, non-foam dosage form;
- Remove white petrolatum or isopropyl palmitate;
- Move outside the claimed numerical ranges; or
- Challenge the half-life limitation in claim 1.
The practical risk is highest for a close-copy formulation and lower for a materially different delivery system.
How strong is the patent estate represented by these claims?
The claim set has moderate formulation strength and limited breadth outside the specified excipient platform.
Strengths
- Claim 7 does not require the 3-to-5-day half-life limitation.
- The claims cover both cream and foam formats.
- The 10%-30% solvent range is commercially meaningful.
- The emulsifier blend is defined by a specific three-component combination.
- Claims 8 and 9 target detailed product embodiments that may be difficult to avoid when a product is closely copied.
Vulnerabilities
- The principal claims depend on a specific excipient combination.
- Claims 8 and 9 are narrow and vulnerable to formulation substitution.
- Claim 1's pharmacokinetic limitation may require substantial testing to prove.
- Claim 4 appears incomplete on its face.
- Prior-art risk may arise from earlier topical roflumilast formulations containing the same solvent, emulsifiers, or emollients.
- The patent does not appear, from the supplied claims, to cover all roflumilast topical formulations.
The strongest enforcement position is likely claim 7 against a cream or foam using the required solvent and emulsifier ranges. Claim 9 may be powerful against an exact or near-exact cream formulation but has a narrow literal scope.
What prior-art and validity issues are most relevant?
The principal validity questions are predictable for formulation patents.
Anticipation
A single prior-art reference would need to disclose every required element, including the roflumilast concentration, water, diethylene glycol monoethyl ether, the three-component emulsifier blend, and, for claim 1, the claimed plasma half-life.
Obviousness
An accused infringer may argue that it would have been obvious to combine:
- A known topical roflumilast formulation;
- Diethylene glycol monoethyl ether as a penetration enhancer or solvent;
- A conventional emulsifier system; and
- Petrolatum or isopropyl palmitate as emollients.
Unexpected pharmacokinetic or dermatologic performance could support nonobviousness, but the evidentiary value would depend on the specification and prosecution record.
Written description and enablement
The patent must support the claimed concentration ranges, dosage forms, emulsifier blend, and half-life result. Claim 1's functional limitation raises a particular enablement question if the patent provides limited guidance for achieving a 3-to-5-day half-life across the full 0.05%-1.0% roflumilast range.
Indefiniteness
Claim 4's missing roflumilast amount is the clearest facial drafting issue in the supplied text. The effect may be confined to claim 4 and its dependents, or it may create broader construction problems depending on how the issued record and specification resolve the language.
Which companies are challenging the roflumilast patent?
The supplied claim set does not identify a Paragraph IV filer, litigation defendant, settlement agreement, or licensee. No challenger, settlement, or license should be inferred from the existence of the patent alone.
The relevant competitive groups are:
| Group |
Likely objective |
| Generic pharmaceutical companies |
Develop an ANDA product while avoiding or invalidating listed formulation patents |
| Branded roflumilast product sponsor |
Preserve formulation exclusivity and defend Orange Book-listed patents |
| Compounding pharmacies |
Market or prepare nonapproved formulations, subject to applicable federal and state law |
| Dermatology drug developers |
Use alternative PDE4 inhibitors, excipients, or delivery systems |
| Contract manufacturers |
Supply creams, foams, and emulsion systems while managing process and formulation know-how |
What manufacturing and geographic barriers matter?
The patent claims are composition claims, so manufacturing-process differences will not necessarily avoid infringement if the finished product contains the claimed ingredients and ranges. A process patent or trade-secret manufacturing method would create a separate barrier.
Key technical barriers include:
- Maintaining a stable emulsion;
- Achieving consistent droplet or foam structure;
- Controlling roflumilast uniformity;
- Managing preservative and excipient compatibility;
- Reproducing topical spreadability and drying behavior;
- Demonstrating batch-to-batch assay and impurity control; and
- Establishing topical bioequivalence.
The claims are United States claims. Equivalent patents in Europe, Japan, Canada, or other jurisdictions would require separate family and legal-status analysis. A U.S. patent does not create direct exclusionary rights outside the United States.
What licensing and settlement issues affect commercial value?
A license may resolve patent risk only if it covers the relevant patent, formulation, territory, field of use, and regulatory pathway. A settlement may also contain launch dates, covenants not to sue, authorized-generic provisions, or restrictions on formulation changes.
No licensing deal or settlement agreement is established by the supplied claims. Commercial diligence should treat the patent as an independent exclusion right unless a binding agreement states otherwise.
Key Takeaways
- Patent 12,005,052 is directed to topical roflumilast formulations, not roflumilast generally.
- Claim 7 is the principal broad formulation claim because it covers foam and cream products without expressly requiring the 3-to-5-day plasma half-life.
- The required emulsifier blend is cetostearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate.
- Diethylene glycol monoethyl ether is required in claims 1 and 7 and is limited to 10%-30% w/w in claim 7.
- Claim 9 creates narrow coverage for a cream containing 25% solvent, 10% emulsifier blend, 10% white petrolatum, and 5% isopropyl palmitate.
- Claim 1 may be harder to enforce because of its pharmacokinetic limitation.
- Claim 4 contains incomplete concentration language as supplied.
- Roflumilast is a small molecule, so generic entry proceeds through the ANDA framework rather than biosimilar regulation.
- Orange Book listing must be confirmed separately; the patent number alone does not establish listing.
- The principal generic design-around options are solvent substitution, emulsifier substitution, dosage-form change, and movement outside the claimed concentration ranges.
FAQs
Does Patent 12,005,052 cover roflumilast cream at 0.3%?
Potentially, but the 0.3% strength alone is insufficient. The product would also need to satisfy the applicable solvent, emulsifier, dosage-form, and, for claim 1, pharmacokinetic limitations.
Can a roflumilast foam avoid the patent by changing the propellant?
Changing the propellant may not avoid claims 7 or 8 if the foam still contains the required roflumilast concentration, diethylene glycol monoethyl ether, emulsifier blend, white petrolatum, and isopropyl palmitate.
Is a different emulsifier blend a meaningful design-around?
Yes. The three-component emulsifier blend is a central limitation in the supplied claims. Replacing one required component may avoid literal infringement, although the doctrine of equivalents could remain relevant.
Does the 3-to-5-day half-life apply to every claim?
No. It expressly appears in claim 1 and is inherited by claims 2 through 6. Claim 7 and its dependent claims 8 and 9 do not include that limitation in the supplied text.
Can a compounded roflumilast formulation infringe these claims?
Potentially. Patent infringement and regulatory status are separate questions. A compounded preparation can still raise patent issues if it meets every limitation of an asserted claim.
References
- United States Patent No. 12,005,052, claims 1-9. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2022). Zoryve (roflumilast) cream prescribing information.
- U.S. Food and Drug Administration. (2023). Zoryve (roflumilast) topical foam prescribing information.
- U.S. Food and Drug Administration. (2024). Zoryve (roflumilast) cream prescribing information for atopic dermatitis.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
- U.S. Food and Drug Administration. (2023). Draft guidance on topical dermatological drug products submitted in abbreviated new drug applications.
